Imatinib

Acute Leukemia

Institute of Hematology & Blood Diseases Hospital, ChinaSmall moleculePhase 4 / ApprovedActive

B

57/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 47/ 100
Competitive Position: 73/ 100

Competitive context

59 Active assets in the Acute Leukemia cohort.

Asset / Sponsor	Phase	Rating
Fludarabine Sawa Ito, MD	Phase 2/3	BB
Cyclophosphamide Sawa Ito, MD	Phase 4	BB
Cytosin-Arabinosid Janssen Research & Development, LLC	Phase 2/3	BB
ETOPOSIDE Nanfang Hospital, Southern Medical University	Phase 2/3	BB
METHOTREXATE SWOG Cancer Research Network	Phase 3	BB

View all 50 →

Same molecule, other indications

Imatinib is also rated in:

chronic myeloid leukemiaDormant

BB

Indicative ·

71 / 100

blast phase chronic myelogenous leukemia, BCR-ABL1 positiveDormant

BB

Indicative ·

71 / 100

B-lymphoblastic leukemia/lymphoma with t(9;22)(q34.1;q11.2)Dormant

BB

Indicative ·

69 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.